

10/667,167


=> file caplus
FILE 'CAPLUS' ENTERED AT 10:38:51 ON 10 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Nov 2004 VOL 141 ISS 20
FILE LAST UPDATED: 9 Nov 2004 (20041109/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 7 SEA FILE=REGISTRY SSS FUL L1
L4 2 SEA FILE=CAPLUS L3

=> d 14 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:267328 CAPLUS
DOCUMENT NUMBER: 140:287372
TITLE: Preparation of 2-(isoxazol-4-yl)pyridines and related compounds as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.
INVENTOR(S): Blumberg, Laura Cook; Munchhof, Michael John
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026865	A1	20040401	WO 2003-IB4005	20030912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

US 2004116473 A1 20040617 US 2003-667167 20030917

PRIORITY APPLN. INFO.: US 2002-412131P P 20020918
US 2003-484580P P 20030702

OTHER SOURCE(S) : MARPAT 140:287372



AB Title compds. I [X = O, S; R1 = (un)saturated aromatic, monocyclic, bicyclic, etc.; R2 = (R3)s; R3 = H, halo, halo-alkyl, etc.; s = 1-5; R4 = H, halo, alkenyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, condensation of ketone II, e.g., prepared from 6-methoxy-4-quinolinecarboxaldehyde in one step, N,N-dimethylformamide di-Me acetal and hydroxylamine afforded isoxazole III. In β 1-transforming growth factors kinase assay, isoxazole III exhibited an IC50 value of 118 nM. Of note, compds. I also possess differential activity, i.e. are selective for β 1-TGF over β 2-TGF and β 3-TGF. Compds. I are claimed useful for the treatment of TGF-related disease states including cancer and fibrotic diseases.

IT 676256-19-2P, 4-[3-(6-Methylpyridin-2-yl)isoxazol-4-yl-]quinoline

676256-20-5P 676256-21-6P, 6-[3-(6-Methylpyridin-2-

yl)isoxazol-4-yl]quinoxaline **676256-22-7P**, 4-Chloro-6-[3-(6-

methylpyridin-2-yl)isoxazol-4-yl]quinoline **676256-23-8P**,

6-Methoxy-4-[3-(6-methylpyridin-2-yl)isoxazol-4-yl]quinoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


RE: TAC (Therapeutic activity); SYN (Synthetic preparation); IM (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Intrapelvic use), BICE (Bicuspidal Study), PREP (Preparation), CSLS (Uses)


(preparation of 2-(isoxazolyl)pyridines and related compds. as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.)

10/667,167


RN 676256-19-2 CAPLUS
CN Quinoline, 4-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA INDEX
NAME)




RN 676256-20-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 7-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]-
(9CI) (CA INDEX NAME)



RN 676256-21-6 CAPLUS
CN Quinoxaline, 6-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA INDEX
NAME)




RN 676256-22-7 CAPLUS
CN Quinoline, 4-chloro-6-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA
INDEX NAME)



RN 676256-23-8 CAPLUS

CN Quinoline, 6-methoxy-4-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:42269 CAPLUS

DOCUMENT NUMBER: 138:106708

TITLE: Preparation of isoxazolylpyrimidines as inhibitors of Src and Lck protein kinases

INVENTOR(S): Bemis, Guy; Gao, Huai; Harrington, Edmund; Leedeboer, Mark; Salituro, Francesco; Wang, Jian

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004492	A1	20030116	WO 2002-US18956	20020614
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2003171389	A1	20030911	US 2002-171895	20020614
US 6689778	B2	20040210		
EP 1417205	A1	20040512	EP 2002-744355	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-302969P	P 20010703
			WO 2002-US18956	W 20020614
OTHER SOURCE(S):		MARPAT 138:106708		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Isoxazolylpyrimidines [e.g., I; wherein A-B = N-O or O-N; G = alkyl, cycloalkyl, alkoxy, thioalkoxy, aryloxy, alkylsulfoxy, amino, etc.; R1 = H, halo, NO₂, (substituted) (C₁-C₆)alkylidene, etc.; R2 = H, (substituted) (C₁-C₆)alkyl, etc.; R3 = H, alkoxy, thioalkoxy, aryloxy, alkylsulfoxy, amino, etc.; R4 = H, halo, NO₂, CN, alkoxy, thioalkoxy, amino, amido, etc.] were prepared. For example, 4-(2-{3-[4-(3-cyclohexyl-5-methylisoxazol-4-yl)pyrimidin-2-ylaminophenoxy}ethyl)piperidin-4-ol (II) was prepared in several steps. These compds. are inhibitors of Src and Lck kinase. For example, compound II provided Ki < 0.1 μM in a Src inhibition assay.

IT 486428-06-2P 486428-47-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazolylpyrimidines as inhibitors of Src and Lck protein kinases)

RN 486428-06-2 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-4-[5-methyl-3-(2-pyridinyl)-4-isoxazolyl]-N-[3-(3-piperidinyl)phenyl] - (9CI) (CA INDEX NAME)




RN 486428-47-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[[3-[[5-methyl-4-[5-methyl-3-(2-pyridinyl)-4-isoxazolyl]-2-pyrimidinyl]amino]phenyl]amino]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall

FILE 'USPATFULL' ENTERED AT 10:39:35 ON 10 NOV 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


FILE 'USPAT2' ENTERED AT 10:39:35 ON 10 NOV 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1

STR



Structure attributes must be viewed using STN Express query preparation.

L3

7 SEA FILE=REGISTRY SSS FUL L1

L5

3 SEA L3

=> d 15 1-3 ibib abs hitstr

L5 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:152251 USPATFULL

TITLE: Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors

INVENTOR(S): Munchhof, Michael J., Salem, CT, UNITED STATES

Blumberg, Laura C., Waterford, CT, UNITED STATES

PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004116473	A1	20040617
APPLICATION INFO.:	US 2003-667167	A1	20030917 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-412131P	20020918 (60)
	US 2003-484580P	20030702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1216	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Novel isothiazole and isoxazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor ("TGF")- β signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 676256-19-2P, 4-[3-(6-Methylpyridin-2-yl)isoxazol-4-yl]-quinoline
 676256-20-5P 676256-21-6P, 6-[3-(6-Methylpyridin-2-yl)isoxazol-4-yl]quinoxaline 676256-22-7P, 4-Chloro-6-[3-(6-methylpyridin-2-yl)isoxazol-4-yl]quinoline 676256-23-8P, 6-Methoxy-4-[3-(6-methylpyridin-2-yl)isoxazol-4-yl]quinoline (preparation of 2-(isoxazolyl)pyridines and related compds. as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.)

RN 676256-19-2 USPATFULL


CN Quinoline, 4-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 676256-20-5 USPATFULL

10/667,167


CN 1,2,4-Triazolo[4,3-a]pyridine, 7-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]-
(9CI) (CA INDEX NAME)




RN 676256-21-6 USPATFULL
CN Quinoxaline, 6-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA INDEX
NAME)



RN 676256-22-7 USPATFULL
CN Quinoline, 4-chloro-6-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA
INDEX NAME)



RN 676256-23-8 USPATFULL
CN Quinoline, 6-methoxy-4-[3-(6-methyl-2-pyridinyl)-4-isoxazolyl]- (9CI) (CA
INDEX NAME)



L5 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:244975 USPATFULL
 TITLE: Inhibitors of Src and Lck protein kinases
 INVENTOR(S): Bemis, Guy, Arlington, MA, UNITED STATES
 Gao, Huai, Natick, MA, UNITED STATES
 Harrington, Edmund, South Boston, MA, UNITED STATES
 Salituro, Francesco, Marlboro, MA, UNITED STATES
 Wang, Jian, Boston, MA, UNITED STATES
 Ledeboer, Mark, Acton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171389	A1	20030911
	US 6689778	B2	20040210
APPLICATION INFO.:	US 2002-171895	A1	20020614 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302969P	20010703 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	VERTEX PHARMACEUTICALS INCORPORATED, 130 Waverly Street, Cambridge, MA, 02139-4242	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1734	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds of formula I: ##STR1##

or a pharmaceutically acceptable derivative thereof, wherein A-B is N--O or O--N and G, R.¹, R.², R.³, and R.⁴ are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of Src and Lck kinase. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 486428-06-2P 486428-47-1P

(preparation of isoxazolylpyrimidines as inhibitors of Src and Lck protein kinases)

RN 486428-06-2 USPATFULL

CN 2-Pyrimidinamine, 5-methyl-4-[5-methyl-3-(2-pyridinyl)-4-isoxazolyl]-N-[3-(3-piperidinyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 486428-47-1 USPATFULL


CN 2-Pyrrolidinemethanol, 1-[3-[[3-[[5-methyl-4-[5-methyl-3-(2-pyridinyl)-4-isoxazolyl]-2-pyrimidinyl]amino]phenyl]amino]propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L5 ANSWER 3 OF 3 USPAT2 on STN

ACCESSION NUMBER: 2003:244975 USPAT2

TITLE: Inhibitors of Src and Lck protein kinases
INVENTOR(S): Bemis, Guy, Arlington, MA, United States
Gao, Huai, Natick, MA, United States

Harrington, Edmund, South Boston, MA, United States
 Salituro, Francesco, Marlboro, MA, United States
 Wang, Jian, Boston, MA, United States
 Ledeboer, Mark, Acton, MA, United States
 PATENT ASSIGNEE(S) : Vertex Pharmaceuticals Incorporated, Cambridge, MA,
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6689778	B2	20040210
APPLICATION INFO.:	US 2002-171895		20020614 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302969P	20010703 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Rao, Deepak	
LEGAL REPRESENTATIVE:	Robidoux, Andrea L. C., Vertex Pharmaceuticals Incorporated	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1647	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds of formula I: ##STR1##

or a pharmaceutically acceptable derivative thereof, wherein A--B is N--O or O--N and G, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of Src and Lck kinase. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 486428-06-2P 486428-47-1P
 (preparation of isoxazolylpyrimidines as inhibitors of Src and Lck protein kinases)
 RN 486428-06-2 USPAT2
 CN 2-Pyrimidinamine, 5-methyl-4-[5-methyl-3-(2-pyridinyl)-4-isoxazolyl]-N-[3-(3-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 486428-47-1 USPAT2
 CN 2-Pyrrolidinemethanol, 1-[3-[[3-[5-methyl-4-[5-methyl-3-(2-pyridinyl)-4-isoxazolyl]-2-pyrimidinyl]amino]phenyl]amino]propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



=>